1. Home
  2. Browse
  3. PRJCA002672
Accession PRJCA002672
Title Neoantigen vaccination trial for advanced tumor patients
Relevance Medical
Data types Whole genome sequencing
Genome sequencing
Organisms Homo sapiens
Description Due to their high tumor specificity and immunogenicity, neoantigens have been considered as ultimate targets for cancer immunotherapy. Neoantigen-based vaccines have demonstrated promising efficacy for several cancer types. To further investigate the anti-tumor potentials for other types of solid tumors, we designed a peptide-based neoantigen vaccine, iNeo-Vac-P01, and conducted a single-arm, open-labeled, investigator-initiated clinical trial (NCT03662815).Personalized neoantigen vaccines were designed and manufactured according to our bioinformatics analysis results from the whole-exome sequencing (WES) of tumor and peripheral blood cell DNAs. Patients were scheduled to be vaccinated subcutaneously (s.c.) with adjuvant on days 1, 4, 8, 15, 22 (prime phase), and days 78, 162 (boost phase). Additional immunizations were administrated every 2~3 months as per patient's potential benefit. The safety and efficacy were assessed through adverse events, progression-free survival (PFS), overall survival (OS) and other parameters.
Sample scope Multiisolate
Release date 2020-05-12
Publication
PubMed ID Article title Journal name DOI Year
32439700 A pan-cancer clinical study of personalized neoantigen vaccine monotherapy in treating patients with various types of advanced solid tumors Clinical Cancer Research 10.1158/1078-0432.CCR-19-2881 2020
Grants
Agency program Grant ID Grant title
Ministry of Science and Technology of the People's Republic of China (MOST) National Key Technologies R&D Program 2017YFC0908600
Submitter shuqing    chen  (chenshuqing@zju.edu.cn)
Organization Zhejiang University
Submission date 2020-05-12

Project Data

Resource name Description
BioSample (44)  show -